Dnmt1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DNA Methyltransferase 1 (DNMT1) is the primary maintenance DNA methyltransferase responsible for copying DNA methylation patterns during DNA replication. It catalyzes the addition of methyl groups to cytosine residues in CpG dinucleotides, playing essential roles in genomic imprinting, X-chromosome inactivation, and cellular differentiation. DNMT1 dysfunction is implicated in Alzheimer's disease, Parkinson's disease, and various cancers.
| DNMT1 Protein |
|---|
| Protein Name | DNA Methyltransferase 1 |
| Gene | [DNMT1](/genes/dnmt1) |
| UniProt ID | [P26358](https://www.uniprot.org/uniprot/P26358) |
| PDB ID(s) | 3AV0, 4WXX |
| Molecular Weight | 183 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | DNA methyltransferase family |
| Expression | Ubiquitous, high in proliferating cells |
¶ Domain Architecture
DNMT1 contains multiple functional domains:
-
N-terminal regulatory domain:
- RFTS domain (1-289): Targets DNMT1 to replication foci
- Zn-binding domain (290-367): CXXC motif for CpG island recognition
- BAH domain (375-500): Bromo-adjacent homology, protein interactions
-
C-terminal catalytic domain (501-1620):
- S-adenosylmethionine (SAM) binding site: Methyl donor
- Catalytic loop: Contains conserved motifs for methyl transfer
- Maintenance methylation: Recognizes hemimethylated CpG sites
- Replication foci targeting: Binds PCNA at replication forks
- Allosteric activation: Binding to unmethylated DNA stimulates activity
- CpG methylation: 5-methylcytosine formation
- Epigenetic inheritance: Maintains methylation patterns through cell division
- Hemimethylated substrate recognition: Preferred substrate
- Gene silencing: Methylation of promoter CpG islands represses transcription
- Genomic imprinting: Parent-of-origin-specific methylation
- X-chromosome inactivation: Random silencing in females
- Cell differentiation: Lineage-specific methylation patterns
- DNA repair: Methylation guides repair machinery
- Chromatin structure: Histone modifications work with DNA methylation
DNMT1 alterations in AD include:
- Global hypomethylation: Reduced DNA methylation in AD brain
- Specific gene changes: APP, BACE1 promoter methylation altered
- Age-related changes: DNMT1 activity declines with age
- Therapeutic potential: DNMT modulators being explored
- α-Synuclein methylation: DNMT1 affects SNCA methylation
- Global changes: Altered methylation patterns in PD brain
- Environmental factors: Pesticide exposure affects DNMT1
- Hyperactivity: DNMT1 overactive in many cancers
- Tumor suppressor silencing: Methylation of growth regulatory genes
- Therapeutic target: DNMT inhibitors used in cancer therapy
- Immunodeficiency: Caused by DNMT1 mutations
- Centromeric instability: Chromosome abnormalities
- Facial dysmorphism: Characteristic features
| Drug |
Type |
Approval |
Indication |
| Azacitidine |
Nucleoside analog |
2004 |
MDS, AML |
| Decitabine |
Nucleoside analog |
2006 |
MDS, AML |
| Guadecitabine |
Second-generation |
Clinical trials |
Various |
- Global effects: Non-selective demethylation
- Toxicity: Cytopenia, gastrointestinal effects
- Blood-brain barrier: Limited penetration
The study of Dnmt1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.